Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

KaloBios to Present at JMML International Symposium


Posted on: 29 Nov 16

BRISBANE, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Dr. Tariq Arshad, acting Chief Medical Officer, will present on the potential for lenzilumab at the 2016 Juvenile Myelomonocytic Leukemia (JMML) International Symposium in San Diego, Calif., December 1-2, 2016.

KaloBios plans to assess interim data from its Phase 1 study of lenzilumab in chronic myelomonocytic leukemia (CMML), a rare hematologic cancer in older adults, to determine the feasibility of commencing a Phase 1 study in JMML, a rare pediatric form of CMML with high unmet medical need and no FDA-approved therapies. In July 2016, KaloBios initiated dosing in a Phase 1 clinical trial in patients with CMML to identify the maximum tolerated or recommended Phase 2 dose and to assess its safety, pharmacokinetics, and clinical activity. More information, including medical centers conducting the trial, can be found at https://clinicaltrials.gov/show/NCT02546284.

Details of the JMML International Symposium presentation follow:

Title: Potential Use of KB003/Lenzilumab in JMML
Presenter: Tariq Arshad, MD, MBA, KaloBios Pharmaceuticals   
Date: Thursday, December 1, 2016
Time: 5:00 – 5:20 p.m. PST
Session: Update on Clinical Trials, Moderator: Charlotte Niemeyer, MD, University of Freiburg

For more information on the conference, please visit https://thejmmlfoundation.wildapricot.org/event-2150399.

About Lenzilumab

Lenzilumab is a Humaneered® recombinant monoclonal antibody that targets and is an antagonist of soluble Granulocyte Macrophage – Colony Stimulating Factor (GM-CSF), a cytokine suggested to be central to the inflammation and activation of certain immune cells. Lenzilumab has been studied for its ability to limit hypersensitivity to GM-CSF signaling, which appears to be a key feature in many CMML and JMML patients, and GM-CSF inhibition may affect the growth of leukemic cells in patients. Lenzilumab has been tested in more than 90 subjects in previous clinical trials in rheumatoid arthritis, asthma and healthy volunteers, and was found to be generally safe and well tolerated.

About KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.

GlobeNewswire
globenewswire.com

Last updated on: 29/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.